Novo Nordisk Receives FDA Approval for Fiasp (insulin aspart injection), a New Fast-Acting Mealtime Insulin

PLAINSBORO, N.J., Sept. 29, 2017 /PRNewswire/ — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved Fiasp (insulin aspart injection) 100 Units/mL, a fast-acting mealtime insulin indicated to improve glycemic…

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us